BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets close in 2 hrs 4 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
288.55+3.42 (+1.20%)
As of 1:56PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close285.13
Bid288.34 x 200
Ask288.41 x 100
Day's Range284.27 - 288.80
52 Week Range223.02 - 333.65
Avg. Volume1,807,442
Market Cap62.31B
PE Ratio (TTM)17.04
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
    Motley Fool35 minutes ago

    Better Buy: Biogen Inc. vs. Gilead Sciences Inc.

    How Biogen and Gilead Sciences stack up in a battle of big biotech stocks.

  • American City Business Journals7 hours ago

    Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer

    A new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by California venture capital firm Canaan Partners.

  • Here's Why Celgene's Latest Drug Is So Exciting
    Motley Fool4 days ago

    Here's Why Celgene's Latest Drug Is So Exciting

    The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.